Efficiency and specificity are two key attributes of anti-cancer drugs including genetic therapeutic agents. We suggest a way to improve specificity of gene therapy drugs based on the ability of 3 0 -untranslated regions (UTR) of some mRNAs selectively stabilize transcripts only during cell division. The mRNAs of genes encoding DNA methyltransferase I (DNMT1) and topoisomerase IIa (TOP2A) are among such transcripts. When inserted into genetic constructs designed to produce therapeutic protein in tumor cells, such 3 0 -UTR would lead to diminished effect of therapeutic protein on normal cells, which are characterized by low or absent proliferative activity. However, when included in gene expression cassette, these 3 0 -UTR might result in decreased transgene expression, thus, overweighting the advantage of increased specificity of expression. We showed that DNMT1 and to the lesser extent TOP2A 3 0 -UTR do not alter significantly therapeutic transgene expression level in tumor cells, thus, confirming the functionality of the proposed approach.
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In cancer gene therapy, one of the major challenges is a specific expression of therapeutic transgene in tumor cells to provide minimal effect on normal cells. To achieve tumor specificity of transgene expression, several approaches are used. This includes delivery of expression construct specifically to tumor cells, targeting the transgene product for a molecular pathway which is specific for tumor cells, confining transgene transcription to tumor cells and their combinations. Tumor-specific transgene expression is usually achieved through transcriptional control with tumor-specific promoters driving transgene expression. One of such promoters is human telomerase reverse transcriptase promoter. 1,2 However, despite the high selectivity of tumor-specific promoters (including human telomerase reverse transcriptase promoter), they still possess some transcriptional activity in non-tumor cells. 3 Such nonspecific expression in nontumor cells might have undesired consequences and affect safety profile of the drug, which is acknowledged to be of a great concern. 4 To meet this problem, further increase in specificity of gene therapy drugs is highly desirable. Efficiency of protein production in cells is determined by several factors including transcription rate, transcript stability, translation efficiency and protein stability. To assure efficient and specific therapeutic transgene expression in tumor cells, the transcription rate is currently the main concern. Nevertheless, the actively transcribed genes can still have low expression because of low stability of their mRNAs. Therefore, regulation of mRNA stability may provide a valuable tool in increasing gene expression specificity in cancer cells. One of the characteristic features of tumor cells is their high proliferative activity. Analysis of the published data revealed two transcripts, which are selectively stabilized during cell division, DNA methyltransferase I (DNMT1) and topoisomerase IIa (TOP2A). It was reported that a 54-nucleotide highly conserved element within 3 0 -untranslated regions (3 0 -UTR) of the DNMT1 mRNA can confer a growth-dependent regulation of its own as well as heterologous transcripts by destabilizing mRNA in growth arrested, but not in dividing, cells. 5 The similar effect was described for TOP2A. 6, 7 This property prompted us to use DNMT1 and TOP2A 3 0 -UTRs in gene expression cassettes for delivering therapeutic genes to tumor cells aiming to improve specificity of transgene expression in proliferating tumor cells compared with normal cells with low or absent proliferative activity.
To be practical, the insertion of the 3 0 -UTRs into expression cassette should not significantly affect the rate of transgene expression level in dividing cells and keep it high enough to produce therapeutic effect.
To experimentally check the ability of DNMT1 and TOP2A 3 0 -UTRs to support exogenous protein production, we first compared expression of dEGFP reporter gene linked to conventional SV40 early mRNA polyadenylation signal (3SV40) or DNMT1 or TOP2A 3 0 -UTR in NCI-H1299 cells. As evident from Figure 1a , DNMT1 or TOP2A 3 0 -UTR did not significantly affected transgene expression. In two other cell lines tested, HeLa B and Calu-I, dEGFP was also expressed at comparable levels with all 3 0 -UTRs used (though with some decline evident for TOP2A 3 0 -UTR; Figure 1a) . (Figure 1b) . Quantification of Rluc activity revealed some variations between cell lines in transgene expression when linked to DNMT1 or TOP2A 3 0 -UTR, but the observed decrease in the expression has not exceeded fivefold compared with the transgene linked to 3SV40 sequence. In addition, comparison of dEGFP and Rluc expression linked to different 3 0 -UTRs ( Figures  1a and b) indicates that effect of 3 0 -UTRs on the expression efficiency might vary depending on the transgene, with the DNMT1 3 0 -UTR being generally superior over TOP2A 3 0 -UTR in terms of expression efficiency. Finally, although the ability to selectively stabilize exogenous transcripts in S-and S/G 2 /M-phases of cell cycle has been experimentally demonstrated for DNMT1 and TOP2A 3 0 -UTRs, respectively, 5,7 we assayed the ability of DNMT1 3 0 -UTR to suppress Rluc expression in non-dividing quiescent cells. Expression of Rluc linked to 3SV40 was not altered in primary human bronchial epithelial cells after growth supplement deprivation (which leads to partial depletion of cells in S and G 2 /M phases). 8 However, the expression tends to drop in growth supplement-deprived cells when the transgene was Figure 1c ). This confirms DNMT1 3 0 -UTR-dependent suppression of transgene expression in G 0 /G 1 (i.e., non-dividing) cells, even the quiescence in the experimental settings used is known not to be complete. 8 Thus, along with the capacity to specifically stabilize exogenous transcripts only in dividing cells, DNMT1 3 0 -UTR and to the lesser extent TOP2A 3 0 -UTR are capable to support efficient transgene expression at the level comparable to that achieved with traditionally used polyadenylation signals.
To ultimately prove the utility of DNMT1 and TOP2A 3 0 -UTR usage in genetic constructs to drive therapeutic gene expression in tumor cells we assayed their performance in prototypic expression cassettes designed to drive herpes simplex virus thymidine kinase (HSVtk) suicide gene expression under control of tumor-specific human telomerase reverse transcriptase promoter nucleotides À206y þ 37. 3, 9, 10 Plasmids with human telomerase reverse transcriptase promoter-driven HSVtk cDNA linked to either reference 3SV40 sequence or DNMT1 or TOP2A 3 0 -UTR were used to transfect NCI-H1299 cells followed by gancyclovir exposure. As evident from Figure 1d , transfection of all plasmids was equally efficient in eliciting gancyclovir-dependent tumor cell death, independently of the 3 0 -UTR used. This demonstrates that DNMT1 and TOP2A 3 0 -UTRs perform as good as one of the commonly used 3SV40 sequence in terms of supporting therapeutic transgene expression in tumor cells at the level high enough to cause their death.
Summarizing, we proposed a novel method to improve tumor specificity of transgene expression which is based on selective stabilization of transcript in dividing tumor cells compared with non-dividing non-tumor cells achieved by using specific 3 0 -UTRs exemplified by 3 0 -UTRs of human DNMT1 and TOP2A transcripts, and demonstrated the justifiability of the suggested concept. Application of this strategy would result in increased specificity of anti-cancer gene therapy drugs without adverse effect on their efficiency, thus, improving safety of gene therapy approaches in cancer treatment, which is of a great importance.
